Amy S. Clark, MD, MSCE

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial , JAMA Oncol, 12(9): 2026,1008-1017

Magbanua MJM, Wolf DM, Yau C, Manon NA, Sayaman RW, Brown Swigart L, Hirst G, Li W, Isaacs C, Shatsky R, Clark AS, Zimmer A, Mukhtar R, Delson AL, Perlmutter J, Pohlmann PR, Hylton NM, Nanda R, Yee D, Symmans WF, Esserman LJ, Rugo HS, DeMichele A, van 't Veer LJ. Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy , medRxiv [Preprint]: 2026

Ana C. Garrido-Castro1, Tianyu Li2, Se Eun Kim2, Jennifer Desrosiers1, Rita Nanda3, Yara Abdou4, Amy S. Clark5, Ruth Sacks6, Thomas O’Connor1, Natalie Sinclair1, Steve Lo7, Grace Audahl1, Eileen Wrabel1, Tess O’Meara1, Tanya E. Keenan1,8*, Nancy U. Lin1, Harold J. Burstein1, Elizabeth A. Mittendorf1, Nabihah Tayob2, Sara M. Tolaney1 SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative metastatic breast cancer , ESMO Open, 11(Supplement 4): 2026,107447

Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA. Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes , Stat Med, 45(8-9): 2026

Phun J, Clark A, Zhang J, Nayak, A. Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals , Laboratory Investigation, 106(3): 2026,104474

Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy , Cancer Cell, 44(3): 2026,449-454

Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES. CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy , J Natl Compr Canc Netw., 24(3.5): 2026,CLO26-104

J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study , Clin Cancer Res, 32(4 suppl): 2026,PS4-07-15

Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC) , Clin Cancer Res, 32(4 Suppl): 2026,PD10-02

Pohlmann PR, Rugo HS, Yau C, Yee D, Chien AJ, Williams NO, Wallace AM, Boughey JC, Vaklavas C, Arora M, Borges V, Clark AS, Omene C, Isaacs C, Stringer-Reasor E, Nanda R, Falkson C, Albain KS, Chan N, Roussos Torres ET, Rozenblit M, Tseng J, Bommakanti S, Nangia C, Brown-Swigart L, Hirst GL, Pasricha N, Kretzer CH, Perlmutter J, Borowsky A, Symmans WF, van 't Veer LJ, Hylton N, Esserman LJ Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788 in the neoadjuvant setting: Results from the I-SPY2.2 trial , Clin Cancer Research, 32(4 Suppl): 2026,PD10-02